Chronic GvHD-associated serositis and pericarditis

J. T. Leonard, Laura Newell, Gabrielle Meyers, Brandon Hayes-Lattin, J. Gajewski, Stephen Heitner, Stephanie Nonas, B. Allen, A. Stentz, R. Frires, Richard Maziarz, S. G. Holtan

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Serositis is a rare manifestation of chronic GvHD (cGvHD). No risk factors or laboratory changes associated with this syndrome have been recognized to date, and outcomes have not been described in a large series. We searched our institutional database for patients undergoing allogeneic hematopoietic cell transplant identified as having serositis or pericarditis. Laboratory studies from prior to diagnosis, at diagnosis and post diagnosis of serositis, as well as outcomes from invasive procedures were included. Twenty patients met criteria for cGvHD-associated serositis, and all but three patients had a prior diagnosis of cGvHD. Fifteen were male, and the complication occurred in the setting of immunosuppressant taper in 12 cases. Ten patients required invasive interventions, including pericardial window or stripping. A significant increase in blood monocytes and decrease in serum albumin were identified at diagnosis compared with pre-diagnosis. Out of 20 patients, 17 were treated with steroids, with 12 demonstrating a complete response. These data suggest that cGvHD-associated serositis occurs mainly in the setting of treated as opposed to de novo cGvHD and biomarkers associated with the syndrome include a decrease in albumin and an increase in absolute monocyte count. Outcome data from larger series are required to better understand the optimal management of this rare complication.

Original languageEnglish (US)
Pages (from-to)1098-1104
Number of pages7
JournalBone Marrow Transplantation
Volume50
Issue number8
DOIs
StatePublished - Aug 8 2015

Fingerprint

Serositis
Pericarditis
Monocytes
Immunosuppressive Agents
Serum Albumin
Albumins
Biomarkers
Steroids
Databases
Transplants

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Chronic GvHD-associated serositis and pericarditis. / Leonard, J. T.; Newell, Laura; Meyers, Gabrielle; Hayes-Lattin, Brandon; Gajewski, J.; Heitner, Stephen; Nonas, Stephanie; Allen, B.; Stentz, A.; Frires, R.; Maziarz, Richard; Holtan, S. G.

In: Bone Marrow Transplantation, Vol. 50, No. 8, 08.08.2015, p. 1098-1104.

Research output: Contribution to journalArticle

Leonard, J. T. ; Newell, Laura ; Meyers, Gabrielle ; Hayes-Lattin, Brandon ; Gajewski, J. ; Heitner, Stephen ; Nonas, Stephanie ; Allen, B. ; Stentz, A. ; Frires, R. ; Maziarz, Richard ; Holtan, S. G. / Chronic GvHD-associated serositis and pericarditis. In: Bone Marrow Transplantation. 2015 ; Vol. 50, No. 8. pp. 1098-1104.
@article{43781b83b9e84239bcb2eef70cac92ef,
title = "Chronic GvHD-associated serositis and pericarditis",
abstract = "Serositis is a rare manifestation of chronic GvHD (cGvHD). No risk factors or laboratory changes associated with this syndrome have been recognized to date, and outcomes have not been described in a large series. We searched our institutional database for patients undergoing allogeneic hematopoietic cell transplant identified as having serositis or pericarditis. Laboratory studies from prior to diagnosis, at diagnosis and post diagnosis of serositis, as well as outcomes from invasive procedures were included. Twenty patients met criteria for cGvHD-associated serositis, and all but three patients had a prior diagnosis of cGvHD. Fifteen were male, and the complication occurred in the setting of immunosuppressant taper in 12 cases. Ten patients required invasive interventions, including pericardial window or stripping. A significant increase in blood monocytes and decrease in serum albumin were identified at diagnosis compared with pre-diagnosis. Out of 20 patients, 17 were treated with steroids, with 12 demonstrating a complete response. These data suggest that cGvHD-associated serositis occurs mainly in the setting of treated as opposed to de novo cGvHD and biomarkers associated with the syndrome include a decrease in albumin and an increase in absolute monocyte count. Outcome data from larger series are required to better understand the optimal management of this rare complication.",
author = "Leonard, {J. T.} and Laura Newell and Gabrielle Meyers and Brandon Hayes-Lattin and J. Gajewski and Stephen Heitner and Stephanie Nonas and B. Allen and A. Stentz and R. Frires and Richard Maziarz and Holtan, {S. G.}",
year = "2015",
month = "8",
day = "8",
doi = "10.1038/bmt.2015.105",
language = "English (US)",
volume = "50",
pages = "1098--1104",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Chronic GvHD-associated serositis and pericarditis

AU - Leonard, J. T.

AU - Newell, Laura

AU - Meyers, Gabrielle

AU - Hayes-Lattin, Brandon

AU - Gajewski, J.

AU - Heitner, Stephen

AU - Nonas, Stephanie

AU - Allen, B.

AU - Stentz, A.

AU - Frires, R.

AU - Maziarz, Richard

AU - Holtan, S. G.

PY - 2015/8/8

Y1 - 2015/8/8

N2 - Serositis is a rare manifestation of chronic GvHD (cGvHD). No risk factors or laboratory changes associated with this syndrome have been recognized to date, and outcomes have not been described in a large series. We searched our institutional database for patients undergoing allogeneic hematopoietic cell transplant identified as having serositis or pericarditis. Laboratory studies from prior to diagnosis, at diagnosis and post diagnosis of serositis, as well as outcomes from invasive procedures were included. Twenty patients met criteria for cGvHD-associated serositis, and all but three patients had a prior diagnosis of cGvHD. Fifteen were male, and the complication occurred in the setting of immunosuppressant taper in 12 cases. Ten patients required invasive interventions, including pericardial window or stripping. A significant increase in blood monocytes and decrease in serum albumin were identified at diagnosis compared with pre-diagnosis. Out of 20 patients, 17 were treated with steroids, with 12 demonstrating a complete response. These data suggest that cGvHD-associated serositis occurs mainly in the setting of treated as opposed to de novo cGvHD and biomarkers associated with the syndrome include a decrease in albumin and an increase in absolute monocyte count. Outcome data from larger series are required to better understand the optimal management of this rare complication.

AB - Serositis is a rare manifestation of chronic GvHD (cGvHD). No risk factors or laboratory changes associated with this syndrome have been recognized to date, and outcomes have not been described in a large series. We searched our institutional database for patients undergoing allogeneic hematopoietic cell transplant identified as having serositis or pericarditis. Laboratory studies from prior to diagnosis, at diagnosis and post diagnosis of serositis, as well as outcomes from invasive procedures were included. Twenty patients met criteria for cGvHD-associated serositis, and all but three patients had a prior diagnosis of cGvHD. Fifteen were male, and the complication occurred in the setting of immunosuppressant taper in 12 cases. Ten patients required invasive interventions, including pericardial window or stripping. A significant increase in blood monocytes and decrease in serum albumin were identified at diagnosis compared with pre-diagnosis. Out of 20 patients, 17 were treated with steroids, with 12 demonstrating a complete response. These data suggest that cGvHD-associated serositis occurs mainly in the setting of treated as opposed to de novo cGvHD and biomarkers associated with the syndrome include a decrease in albumin and an increase in absolute monocyte count. Outcome data from larger series are required to better understand the optimal management of this rare complication.

UR - http://www.scopus.com/inward/record.url?scp=84938954954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938954954&partnerID=8YFLogxK

U2 - 10.1038/bmt.2015.105

DO - 10.1038/bmt.2015.105

M3 - Article

VL - 50

SP - 1098

EP - 1104

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 8

ER -